profit from every $100 of sales.
$0$100
908 Devices
$10.06+0.75% today
+70.5% in 1 year
1-year low $5.091-year high $12.87
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $21.46 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What 908 Devices sold, what it kept, and what it did with the cash.
Sales went from $46.9 million in 2022 to $56.2 million in 2025, with $19.5 million of profit last year.
SalesProfit
908 Devices vs. similar companies
908 Devices grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| 908 Devices | 21.5× · Fair price | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads 908 Devices's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 47 | 50 | 48 | 56 | |
| 26 | 25 | 25 | 28 | |
| -35 | -43 | -30 | -26 | |
| -32 | -34 | -25 | -21 | |
| -34 | -36 | -72 | 19 | |
| -1.07 | -1.13 | -2.12 | 0.54 | |
| 55.5% | 50.4% | 51.3% | 50.6% | |
| -75.5% | -84.9% | -62.7% | -45.7% | |
| -71.6% | -72.5% | -151.2% | 34.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 243 | 203 | 159 | 190 |
| Cash | 188 | 121 | 43 | 71 |
| Total debt | 20 | 6 | 4 | 5 |
| Total liabilities | 52 | 37 | 45 | 46 |
| 191 | 165 | 115 | 144 | |
| 31 | 32 | 34 | 36 | |
| -12.6% | -16.8% | -19.9% | -13.7% | |
| -17.6% | -22.0% | -63.0% | 13.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -25 | -30 | -24 | |
| 2 | 2 | 1 | 1 | |
| -23 | -27 | -31 | -25 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 10 | 12 | 10 |
Valuation
- 21.5×
- –
- –
- 1.9×
- 7.4×
- –
- –
- -5.9%
- 4.7%
- 0.0%
Profitability
- 50.6%
- -45.7%
- 34.7%
- -33.3%
- -20.5%
- -25.8%
- -25.5%
- -19.2%
- -20.6%
- 24.2%
Growth
- +6.2%
- –
- +20.1%
- –
- +6.7%
Financial health
- -3.1×
- 0.03
- 2.4%
- –
- 3.58
- 3.25
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 958
Bottom 7%of 888
Top 40%of 600
Bottom 34%of 889
Bottom 15%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.22 | -0.15 | −46.7% |
| Mar 3, 2026 | -0.05 | -0.06 | +16.7% |
| Nov 10, 2025 | -0.15 | -0.12 | −30.4% |
| Aug 5, 2025 | -0.18 | -0.16 | −12.5% |
| May 13, 2025 | -0.22 | -0.27 | +18.5% |
| Mar 4, 2025 | -0.32 | -0.35 | +8.6% |
| Nov 12, 2024 | -0.23 | -0.29 | +20.7% |
| Aug 6, 2024 | -0.32 | -0.34 | +5.9% |
News
Stock Market Today, Nov. 11: Advanced Micro Devices Jumps -- and Not Only Because of CoreWeave's ResultsYahoo Finance · Nov 11, 2026The Zacks Analyst Blog Highlights Arista Networks, Fabrinet, Analog Devices, Advanced Micro Devices and NVIDIAYahoo Finance · Nov 11, 2026The Zacks Analyst Blog Highlights Analog Devices, Taiwan Semiconductor Manufacturing, Texas Instruments and NVIDIAYahoo Finance · Nov 5, 2026Apple’s Biggest Threat Isn’t Android — It’s AAPL's Own Devices, Analyst Says Ahead Of Q4 EarningsYahoo Finance · Oct 31, 2026Living On The Edge With Nvidia, AI Enabler Analog Devices Tickles New Buy ZoneYahoo Finance · Oct 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
59No pass
Philip Fisher
44No pass
Peter Lynch
70Pass
Joel Greenblatt
12No pass
Charlie Munger
44No pass
Terry Smith
40No pass
Questions about 908 Devices
Is 908 Devices a good stock to buy?
A strong, very profitable business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the 908 Devices AI analysis
What does 908 Devices do?
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. It is in Medical - Devices.
Does 908 Devices pay a dividend?
No. 908 Devices does not pay a dividend at the moment.
Is 908 Devices stock halal?
Yes. 908 Devices passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has 908 Devices stock done over the past year?
Up 70.5% over the past twelve months, to $10.06. It traded between $5.09 and $12.87 and is 21.8% below its high.
Who are 908 Devices's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with 908 Devices's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.